Kopran Limited · NSE:KOPRAN
Kopran — Q2 FY2021 Earnings Presentation
22 slides from Kopran's earnings presentation, October 2020
Slide 1: Quarterly Presentation
An Integrated Global Pharmaceutical Company Quarterly Presentation NSE ticker: KOPRAN BSE ticker: 524280 Bloomberg ticker: KOP:IN A Parijat Enterprise Company
Slide 2: Disclaimer
2 This quarterly investor presentation has been prepared by Kopran Limited (“Kopran”) and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied, should no
Slide 3: A Global Pharmaceutical Company
A Global Pharmaceutical Company 3 An integrated pharmaceutical Company, committed to supply International Quality Formulations and Active Pharmaceutical Ingredients (APIs) across the world Our manufacturing facilities and product range have received various accreditations from across the globe State
Slide 4: Business Overview
Business Overview 4 Antihypertensive Atenolol Macrolides Pregabalin Neuromodulator Cephalosporins - Non- Urological Sterile & Sterile Anti infective/Anti Acne Macrolides Sterile Carbapenems Granules Sterile Cephalosporins Located at MIDC Mahad, Maharashtra Sterile Carbapenems Anti-thrombosis 11,900
Slide 5: Focus Areas
Focus Areas 5 Constantly working on process and yield improvements of existing products to make them more competitive Explore, develop and commercialise products 5 filed; for exports market to leverage expertise and US FDA 1 approval received manufacturing capabilities during the quarter Focusing on
Slide 6: Products developed/under development
Products developed/under development 6 Biapenem* Carbapenem Completed Completed Completed Tebipenem* Carbapenem Completed Completed Completed Faropenem# Carbapenem Completed Completed Completed Completed Imipenem$ Carbapenem Completed Completed Q1 FY 21-22 Launching in Q2 FY 2022 Imipenem + Cilastat
Slide 7: Operational Highlights
Operational Highlights Segment-wise Revenue Mix 7 (` Lakhs) (` Lakhs) Urological Urological Advance Intermediate Anti-infective/ Anti-acne Anti-hypertensive 2.54 Anti-hypertensive Steriles 103.34 Cepholosphorin 718.79 Steriles 101.81 6.32 1,081.82 Cepholosphorin 1,414.24 1,283.04 0.81 Anti-thrombosi
Slide 8: Operational Highlights
Operational Highlights Market-wise Revenue mix 8 (` Lakhs) (` Lakhs) 2,129.06 2,532.95 4,603.39 4,219.94 Domestic Exports Domestic Exports
Slide 9: Developing complete range of Carbapenams to solidify the Company's position
9 Developing complete Received US FDA approval for range of Carbapenams to its Anti-hypertensive Drug solidify the Company’s Atenolol position in the segment Plans to capture major share of Developing Undertaking upgradation and the US Atenolol market in the Anti-thrombosis and expansion of 3 blocks
Slide 10: Business Overview
Business Overview 10 Approved by 11 countries including TGA Australia, MCC South Africa, MHRA UK, FMHACA Ethiopia, PPB Kenya, MOH Oman, MOH Yemen, Penicillin-based NDA Uganda, MOH Ivory Coast Finished Dosage GMP Certification by FDA, Forms Government of Maharashtra Non-Penicillin-based WHO GMP Certi
Slide 11: Focus areas
Focus areas 11 Constantly working on process / technology and yield French West Africa, South-East Asia and few Latin improvement measures to make its existing products American markets are the focus countries for competitive and increase profitability expanding our presence and are at the forefront
Slide 12: Operational Highlights
Operational Highlights Region-wise Sales Break-up 12 (%) (%) 0 2 4 1 0 8 9 10 30 52 34 50 Africa South Africa Southeast Asia Africa South Africa Southeast Asia UK Local Latam UK Local Latam
Slide 13: Operational Highlights
Operational Highlights Product-wise Sales Break-up 13 (%) (%) 39 47 53 61 Penicillin Non-Penicillin Penicillin Non-Penicillin
Slide 14: Dossiers filed and planned
14 5 dossier filed in past two 101 dossiers filed in past quarters two quarters 3 dossiers planned for 100+ dossiers planned for filing by end of Q4 2020-21 filing by end of Q4 2020-21
Slide 15: ioacNh
ioacNh
Slide 16: Quarterly Snapshot
Quarterly Snapshot 16 (` Lakhs) (` Lakhs) (` Lakhs) 2,674.50 262.30 12,440.21 12,454.44 2,363.45 222.83 10,158.25 196.65 8,921.99 8,755.77 186.10 1,356.16 141.69 1,209.18 1,108.23 Q-2 Q-3 Q-4 Q-1 Q-2 Q-2 Q-3 Q-4 Q-1 Q-2 Q-2 Q-3 Q-4 Q-1 Q-2 2019-20 2019-20 2019-20 2020-21 2020-21 2019-20 2019-20 2019
Slide 17: Building shareholder value year on year…
Building shareholder value year on year… 17 (` Lakhs, %) (%) (X) 0.57 4,914 5,037.95 33% 0.51 4,696 4,005 20% 30% 0.41 14% 13% 0.29 17% 15% 13% 15% 15% 15% 11% Q-2 Q-3 Q-4 Q-1 2017-18 2018-19 2019-20 H1 2020-21 Q-2 Q-3 Q-4 Q-1 2017-18 2018-19 2019-20 H1 2020-21 2017-18 2018-19 2019-20 H1 2020-21 EBD
Slide 18: Equity share capital and key financials
18 (` Lakhs) Equity share capital 4,324.89 4,324.89 4,324.89 Other equity 17,722.32 14,643.12 12,522.68 Networth 22,047.21 18,968.01 16,847.57 Fixed Assets (net) 14,012.88 14,139.16 13,691.55 Borrowings 6,291.5 7,806.19 8,656.32 Sales/Other Income 24,894.64 36,013.01 36,095.99 EBIDTA 5,037.94 4,695.
Slide 19: Board of Directors
Board of Directors 19 Executive Vice Chairman Director Independent Director Independent Director Independent Director Independent Director Director Director
Slide 20: Shareholding pattern
20 (%) 2.41 43.78 53.82 Promoters Non-institutions Financial Institutions
Slide 21: Kopran Ltd. is an integrated Pharmaceutical Company
21 Kopran Ltd. is an integrated Pharmaceutical Company, committed to manufacture and supply International Quality Formulations and Active Pharmaceutical Ingredients worldwide. Kopran's manufacturing facilities and products have accreditations across all the continents. Research & Development for New
Slide 22: Thank You